BioGaia AB (FRA:BGLA)
€ 9.115 -0.035 (-0.38%) Market Cap: 931.59 Mil Enterprise Value: 835.03 Mil PE Ratio: 31.83 PB Ratio: 6.64 GF Score: 95/100

Q1 2019 Biogaia AB Earnings Call Transcript

May 08, 2019 / 07:30AM GMT
Release Date Price: €8.39 (-0.24%)
Operator

Ladies and gentlemen. Welcome to the BioGaia Q1 report 2019. Today, I'm pleased to present Isabelle Ducellier, CEO; and Margareta Hagman, CFO. (Operator Instructions) Speakers, please begin.

Isabelle Valerie Ghislaine Ducellier;publ;CEO
BioGaia AB

()-

Yes, good morning and thank you. Isabelle here. Welcome to my second telephone conference, but this time regarding the quarter 1 2019.

I would like to underline 4 dimensions regarding this quarter. Next slide, please. The first one is that we have actually strong sales growth of our products in both Pediatrics and Adult segment. And especially in Adult segment, we have an increase by 54%.

Secondly, I would like as well to emphasize strong sales growth for BioGaia Protectis drops; BioGaia Protectis tablets, which is quite unusual, so it's worth mentioning it; and BioGaia Prodentis lozenges mainly driven by Japan.

Thirdly, I think it is very worth noticing that we have extremely strong growth in the Asia Pacific region, with Quarter 1 at plus 80%. And

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot